LEXINGTON, Mass.--(BUSINESS WIRE)--March 21, 2006--Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today reported that enrollment has been completed in the Company’s second Phase III trial for SANCTURA XR. SANCTURA XR is the once-daily formulation of SANCTURA(R), which is currently marketed for overactive bladder. Earlier this month, the Company reported the completion of enrollment in the first of its two Phase III trials.
